Genprex (GNPX) Stock Overview

A clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. More details

GNPX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Earnings have grown 1.8% per year over the past 5 years

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been substantially diluted in the past year

Does not have a meaningful market cap ($8M)

Volatile share price over the past 3 months compared to the US market

GNPX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Genprex, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Genprex
Historical stock prices
Current Share Price	US$0.79
52 Week High	US$55.00
52 Week Low	US$0.76
Beta	-0.93
1 Month Change	-39.38%
3 Month Change	-57.63%
1 Year Change	-94.53%
3 Year Change	-99.90%
5 Year Change	-99.90%
Change since IPO	-99.90%

Recent updates

Analysis Article • Aug 16

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Analysis Article • Jan 31

Here's Why We're Watching Genprex's (NASDAQ:GNPX) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysis Article • Oct 12

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Aug 15

Genprex stock rises 13% on safety panel nod to continue trial of Reqorsa/Tagrisso combo for lung cancer

Genprex (NASDAQ:GNPX) stock rose ~13% on Aug. 15 after the company said that the Safety Review Committee (SRC) approved continuation of a phase 1/2 trial of Reqorsa in combination with AstraZeneca's Tagrisso (osimertinib) to treat patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Tagrisso. The SRC decision followed a review of the first group of patients in the phase 1 portion of the phase 1/2 study called Acclaim-1. "The SRC approval to advance Acclaim-1 to the higher dose in the second cohort of patients is an important milestone that further supports REQORSA's safety profile and brings us one step closer to bringing this potentially ground-breaking gene therapy approach to treating NSCLC to the patients who need it most," said Genprex Chief Medical Officer Mark Berger. The trial includes up to three sequential dose escalation groups, the company said in an Aug. 15 press release.

Analysis Article • Jun 14

We're Not Very Worried About Genprex's (NASDAQ:GNPX) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Analysis Article • Feb 09

Here's Why We're Not Too Worried About Genprex's (NASDAQ:GNPX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Seeking Alpha • Nov 19

Genprex: Limited Clinical Data To Justify Risk

GNPX is a clinical-stage biotech company developing gene therapies for the treatment of cancer and diabetes. REQORSA—the company's main pipeline molecule—is targeting the Non-Small-Cell Lung Cancer Market. GNPX's share price is currently trading at around $2 after a quick fall from grace (from $15/share) following its IPO in early 2018. Although a low share price may be an attractive entry point, I believe the company has not yet produced any reliable proof of the clinical efficacy of its therapy. In this article, I will argue a neutral position on GNPX discussing the company's technology, market, and clinical data, to present a balanced view on both risk and opportunity.

Analysis Article • Oct 27

We Think Genprex (NASDAQ:GNPX) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Jun 11

Genprex (NASDAQ:GNPX) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

Shareholder Returns

	GNPX	US Biotechs	US Market
7D	-5.1%	-4.9%	-1.0%
1Y	-94.5%	28.1%	23.3%

Return vs Industry: GNPX underperformed the US Biotechs industry which returned 30% over the past year.

Return vs Market: GNPX underperformed the US Market which returned 24.4% over the past year.

Price Volatility

Is GNPX's price volatile compared to industry and market?
GNPX volatility
GNPX Average Weekly Movement	12.8%
Biotechs Industry Average Movement	10.9%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.2%

Stable Share Price: GNPX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: GNPX's weekly volatility has decreased from 39% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2009	13	Ryan Confer	www.genprex.com

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. The company’s technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form.

Genprex, Inc. Fundamentals Summary

How do Genprex's earnings and revenue compare to its market cap?
GNPX fundamental statistics
Market cap	US$8.39m
Earnings (TTM)	-US$16.73m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-0.5x

P/E Ratio

Is GNPX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GNPX income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$16.73m
Earnings	-US$16.73m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.61
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did GNPX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/05/19 14:25
End of Day Share Price	2026/05/19 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Genprex, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
James Molloy	Alliance Global Partners

Genprex (GNPX) Stock Overview

Rewards

Risk Analysis

Genprex, Inc. Competitors

PharmaCyte Biotech

bioAffinity Technologies

Creative Medical Technology Holdings

NuCana

Price History & Performance

Recent News & Updates

Genprex Inc. Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes

Genprex Inc Receives Patent Grant from the Israel Patent Office for Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Inc Announces Positive Clinical Data on Reqorsa Gene Therapy At Asco Annual Meeting

Genprex, Inc. Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer

New major risk - Financial position

Genprex, Inc. to Present Positive Preclinical Data on Reqorsa Gene Therapy for Lung Cancer At the 2026 AACR Annual Meeting

Recent updates

Genprex Inc. Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy for Type 2 Diabetes

Genprex Inc Receives Patent Grant from the Israel Patent Office for Combination of Reqorsa Gene Therapy and PD-1 Antibodies to Treat Cancer

Genprex Inc Announces Positive Clinical Data on Reqorsa Gene Therapy At Asco Annual Meeting

Genprex, Inc. Present Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer

New major risk - Financial position

Genprex, Inc. to Present Positive Preclinical Data on Reqorsa Gene Therapy for Lung Cancer At the 2026 AACR Annual Meeting

Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

Genprex, Inc. Announces Ip Australia's Intent to Grant Patent for Reqorsa®? Gene Therapy in Combination with Pd-L1 Antibodies to Treat Cancers

Genprex, Inc. Provides Clinical Update on Diabetes Gene Therapy Program

Genprex Regains Compliance with the Bid Price Requirement and Receives Extension to Regain Compliance with Nasdaq Stockholders Equity Requirement

Genprex, Inc. Announces the Publication of Data from Its Acclaim-1 Phase 1 Clinical Trial of Reqorsa®? Gene Therapy in Combination with Tagrisso®? (Osimertinib) in Patients with Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials

Genprex, Inc. has filed a Follow-on Equity Offering in the amount of $3.40002 million.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa Gene Therapy for the Treatment of Lung Cancer At the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Genprex, Inc. has filed a Follow-on Equity Offering in the amount of $2.731003 million.

Genprex Inc Receives Exception to Regain Compliance with Nasdaq Listing Requirements

New major risk - Share price stability

Genprex, Inc. Receives Non-Compliance Letter from Listing Qualifications Staff of the Nasdaq Stock Market

Genprex, Inc. Receives Notice of Allowance for Multiple Patents for Reqorsa®? Gene Therapy with Pd-L1 and Pd-1 Antibodies to Treat Cancers

Genprex, Inc. has withdrawn its Follow-on Equity Offering.

Genprex, Inc., Annual General Meeting, Aug 15, 2025

Genprex Collaborators Present Positive Preclinical Research on Diabetes Gene Therapy At the 2025 American Diabetes Association 85Th Scientific Sessions

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System

Genprex Confirms Regains Compliance with Nasdaq Listing Requirements

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa®? Gene Therapy for the Treatment of Ras Inhibitor Resistant Lung Cancer At the 2025 Aacr Annual Meeting

Genprex Selects to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa®? Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Genprex, Inc. announced delayed annual 10-K filing

Genprex Collaborators to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex Delivery System Is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer

Genprex Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Genprex, Inc. Announces First Patient Has Been Enrolled and Dosed in the Phase 2 Expansion Portion of the Company’S Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy

Genprex Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq® in Extensive Stage Small Cell Lung Cancer

Genprex, Inc. Receives Notice from Nasdaq Regarding Non-Compliance with Stockholders' Equity Requirement

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Highest Dose Group in Phase 1 Portion of Acclaim-3 Clinical Trial of Reqorsa Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cell Lung Cancer

Genprex Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement

Genprex, Inc. Announces Positive Clinical Study Updates from Acclaim-1 and Acclaim-3 Phase 1/2 Clinical Trials in Lung Cancer

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial position

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa Immunogene Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc Announces Executive Changes

New major risk - Shareholder dilution

Genprex, Inc., Annual General Meeting, Jun 18, 2024

Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa Therapy in Combination with Tecentriq to Treat Small Cell Lung Cancer

Genprex, Inc. has completed a Follow-on Equity Offering.

Genprex, Inc. has filed a Follow-on Equity Offering.

Genprex, Inc. Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers

Insufficient new directors

Genprex, Inc. Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators

Genprex, Inc. Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa Therapy in Combination with Tagrisso to Treat Non-Small Cell Lung Cancer

New major risk - Market cap size

Genprex, Inc. to Present Data on the Use of Reqorsa for the Treatment of Lung Cancers At 2023 Aacr-Nci-Eortc International Conference on Molecular Targets and Cancer Therapeutics

Genprex Receives Non-Compliance Notice From Nasdaq

Genprex Appoints Suzanne Thornton-Jones as Senior Vice President, Regulatory Affairs

Genprex, Inc. announced delayed 10-Q filing

Can Genprex (NASDAQ:GNPX) Afford To Invest In Growth?

Genprex, Inc. Receives Fast Track Designation from the FDA for Its Small Cell Lung Cancer Drug Candidate

Genprex, Inc. Grants Chinese Patent for REQORSA(R) Immunogene Therapy in Combination with PD-1 Antibodies to Treat Cancers

Genprex Receives U.S. FDA Fast Track Designation for REQORSA Immunogene Therapy in Combination with Tecentriq for the Treatment of Small Cell Lung Cancer

Genprex, Inc. Receives Safety Review Committee Approval to Advance to Phase 2 Expansion Portion of Acclaim-1 Clinical Trial of REQORSA(R) in Combination with Tagrisso(R) in Advanced Non-Small Cell Lung Cancer

Genprex, Inc. Publishes Positive Clinical Data from Phase 1 Portion of Acclaim-1 Clinical Trial Evaluating Reqorsa Immunogene Therapy in Non-Small Cell Lung Cancer